search
Back to results

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Primary Purpose

Mild and Moderate Renal Impairment

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
LCZ696
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Mild and Moderate Renal Impairment focused on measuring Renal Impairment,, LCZ696

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male, and female subjects of non-child bearing potential,
  2. Subjects were to weigh at least 50 kg to participate in the study,
  3. and body mass index < 40 kg/m2
  4. Subjects were able to communicate well with the investigator, to understand and comply with the requirements of the study;
  5. Subjects were able to understand and sign the written informed consent;

For renal insufficient subjects:

  1. stable renal disease without evidence of renal progressive

    • mild renal function: calculated CrCl of 50-≤80 mL/min
    • moderate renal function: calculated CrCl of 30-<50 mL/min
  2. Vital signs:

    • oral body temperature between 35.0-37.8 °C
    • systolic blood pressure, 95-180 mm Hg
    • diastolic blood pressure, 60-110 mm Hg
    • pulse rate, 54-95 bpm

For healthy subjects only

  1. A serum creatinine with a calculated CrCl of >80 mL/min
  2. Vital signs:

    • oral body temperature between 35.0-37.2 °C
    • systolic blood pressure, 95-140 mm Hg
    • diastolic blood pressure, 60-100 mm Hg
    • pulse rate, 45-90 bpm

Exclusion Criteria:

  1. Current use of ACE inhibitors, valsartan, and drugs that were known as CYP2C9 substrates, potassium-sparing diuretics;
  2. Smokers;
  3. History of renal transplant at any time in the past and on immunosuppressant therapy;
  4. Dialysis patients;
  5. Medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome;
  6. Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance; Other protocol defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LCZ696 400 mg

Arm Description

LCZ696 400 mg once daily for 5 days

Outcomes

Primary Outcome Measures

Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Maximum Peak Plasma Concentration (Cmax) Observed After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Area Under the Concentration-time Curve (AUC0-24) From Time Zero to 24- Hour Post-dose (Day 1), and After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Elimination Half-life (t1/2) After Multiple Dose (Day 5) Administration
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Systemic Clearance From Plasma Following Extravascular Administration (CL/F) After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Accumulation Ratio (Racc) After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Renal Clearance From Plasma (CLr) After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Amount of Drug Excreted Into the Urine From Time Zero to 24-hours Post-dose (Ae0-24) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)

Secondary Outcome Measures

Change in Mean 24-hours Sodium Clearance From Baseline to Day 7
Sodium clearance will be measured in urine from baseline until Day 7

Full Information

First Posted
March 30, 2012
Last Updated
September 25, 2015
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01569815
Brief Title
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Official Title
An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Mild and Moderate Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine the multiple dose pharmacokinetics of LCZ696 and its metabolites in subjects with mild to moderate renal impairment and to evaluate the safety of LCZ696 in this population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild and Moderate Renal Impairment
Keywords
Renal Impairment,, LCZ696

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LCZ696 400 mg
Arm Type
Experimental
Arm Description
LCZ696 400 mg once daily for 5 days
Intervention Type
Drug
Intervention Name(s)
LCZ696
Intervention Description
LCZ696 400 mg once daily
Primary Outcome Measure Information:
Title
Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 1 and day 5
Title
Maximum Peak Plasma Concentration (Cmax) Observed After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 1, day 5
Title
Area Under the Concentration-time Curve (AUC0-24) From Time Zero to 24- Hour Post-dose (Day 1), and After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 1 and day 5
Title
Elimination Half-life (t1/2) After Multiple Dose (Day 5) Administration
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 5
Title
Systemic Clearance From Plasma Following Extravascular Administration (CL/F) After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 5
Title
Accumulation Ratio (Racc) After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 5
Title
Renal Clearance From Plasma (CLr) After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 5
Title
Amount of Drug Excreted Into the Urine From Time Zero to 24-hours Post-dose (Ae0-24) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)
Description
Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)
Time Frame
Day 1 and Day 5
Secondary Outcome Measure Information:
Title
Change in Mean 24-hours Sodium Clearance From Baseline to Day 7
Description
Sodium clearance will be measured in urine from baseline until Day 7
Time Frame
From baseline to Day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male, and female subjects of non-child bearing potential, Subjects were to weigh at least 50 kg to participate in the study, and body mass index < 40 kg/m2 Subjects were able to communicate well with the investigator, to understand and comply with the requirements of the study; Subjects were able to understand and sign the written informed consent; For renal insufficient subjects: stable renal disease without evidence of renal progressive mild renal function: calculated CrCl of 50-≤80 mL/min moderate renal function: calculated CrCl of 30-<50 mL/min Vital signs: oral body temperature between 35.0-37.8 °C systolic blood pressure, 95-180 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 54-95 bpm For healthy subjects only A serum creatinine with a calculated CrCl of >80 mL/min Vital signs: oral body temperature between 35.0-37.2 °C systolic blood pressure, 95-140 mm Hg diastolic blood pressure, 60-100 mm Hg pulse rate, 45-90 bpm Exclusion Criteria: Current use of ACE inhibitors, valsartan, and drugs that were known as CYP2C9 substrates, potassium-sparing diuretics; Smokers; History of renal transplant at any time in the past and on immunosuppressant therapy; Dialysis patients; Medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome; Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance; Other protocol defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Neuss
ZIP/Postal Code
41460
Country
Germany
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
117292
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Belgrade
Country
Serbia

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

We'll reach out to this number within 24 hrs